Taken together, our present results strongly suggest that depletion of RUNX2 enhances GEM sensitivity of p53-mutated pancreatic cancer cells through the stimulation of TAp73-dependent cell death pathway, and thus RUNX2 might be an attractive molecular target for the treatment of the patients bearing pancreatic cancer regardless of p53 status. The gene discussed is TP53; the disease is pancreatic neoplasm.